Gala­pa­gos CEO Paul Stof­fels bets €225M on a new CAR-T strat­e­gy for the long suf­fer­ing biotech

The deeply trou­bled Eu­ro­pean biotech Gala­pa­gos and its new CEO Paul Stof­fels are go­ing the CAR-T route, and they have a new, €225 mil­lion buy­out de­signed to give them an in­side track over the first-gen ther­a­pies that have made their way in­to the mar­ket.

Just weeks af­ter ink­ing an ex­clu­sive li­cens­ing pact for an an­ti-BC­MA CAR-T out of Chi­na, Dutch biotech Cell­Point has struck a deal to sell the com­pa­ny to Gala­pa­gos, with €125 mil­lion com­ing in cash and an­oth­er €100 mil­lion on the ta­ble for po­ten­tial mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER